Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200 Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.48 and traded as high as $6.74. Cumberland Pharmaceuticals shares last traded at $6.64, with a volume of 26,890 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Up 3.0%

The stock has a market capitalization of $107.71 million, a P/E ratio of -10.13 and a beta of 0.13. The business’s 50 day simple moving average is $7.24 and its two-hundred day simple moving average is $5.50.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%.The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $8.50 million.

Cumberland Pharmaceuticals Announces Dividend

The business also recently disclosed a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were issued a dividend of $1.50 per share.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Cumberland Pharmaceuticals during the second quarter worth $412,000. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter worth $379,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cumberland Pharmaceuticals in the first quarter valued at about $66,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Cumberland Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock valued at $898,000 after purchasing an additional 4,081 shares during the last quarter. Hedge funds and other institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company’s business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States.

Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation.